Browse Category

NASDAQ:ADAP News 19 August 2025 - 16 October 2025

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Stock Price Rollercoaster in 2025 Adaptimmune’s stock has been on a wild ride this year, with extreme price swings in recent weeks grabbing headlines. After languishing in penny-stock territory for months, ADAP suddenly caught fire in late September 2025. On September 19, shares opened at a mere $0.08 but skyrocketed 98% by day’s end to $0.16, then jumped another 30% after-hours to ~$0.20 ts2.tech. This stunning one-day move – without any company-specific catalyst – was accompanied by an enormous volume of 705+ million shares traded (versus ~60 million on an average day) ts2.tech. Market observers noted Adaptimmune as one of
Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Company Overview: Pioneering T-Cell Therapies for Cancer Adaptimmune Therapeutics plc is a UK-based biotech founded in 2008, specializing in T-cell receptor (TCR) engineered cell therapies to fight cancer ts2.tech. The company’s mission has been to “redefine how some of the most challenging-to-treat solid tumors are treated” by harnessing patients’ own T-cells and genetically equipping them to target cancer cells adaptimmune.com. Adaptimmune’s proprietary platform, known as SPEAR T-cells (Specific Peptide Enhanced Affinity Receptor), allows it to design TCRs that recognize tumor-specific antigens (such as MAGE-A4 or NY-ESO-1) and arm patient T-cells with these receptors ts2.tech ts2.tech. In effect, it’s analogous to
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Therapy (Target) Indication Status (2025) Current Ownership TECELRA(afamitresgene, targets MAGE-A4) Synovial sarcoma (unresectable/metastatic) FDA approved Aug 2024 biospace.com; ~16 patients treated in launch year nasdaq.com. Sold to US WorldMeds (2025) adaptimmune.com Letetresgene (lete-cel, NY-ESO-1) MRCLS and synovial sarcoma (advanced solid tumors) Phase II completed (42% response rate) stocktitan.net; FDA Breakthroughdesignation in 2025 stocktitan.net; BLA filing planned for 2025. Sold to US WorldMeds (2025) adaptimmune.com Uzatresegene (uza-cel, next-gen TCR) Solid tumors (MAGE-A4 TCR, partnered with Galapagos) Preclinical/IND-enabling stage; partnership deal $665M signed 2024 fiercebiotech.com. Sold to US WorldMeds (2025) adaptimmune.com PRAME-targeted TCR Multiple cancers (PRAME antigen) Preclinical (IND-enabling on hold to cut costs) biospace.com. Retained by Adaptimmune adaptimmune.com CD70-targeted TCR Hematologic malignancies
8 October 2025
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Sector – Big Deals, Funding, and FDA Drama Pharma & Drug Development – Approvals, Showdowns, and Safety Signals Medical & Clinical Updates – Guidelines and Safety Notices Public Health & Policy – Vaccine Rift, Medicare Cuts, and Wellness Initiatives Sources: Key news and expert quotes were gathered from Fierce Biotech fiercebiotech.com fiercebiotech.com, Fierce Pharma fiercepharma.com fiercepharma.com, Fierce Healthcare fiercehealthcare.com fiercehealthcare.com, STAT News statnews.com statnews.com, the Florida Phoenix floridaphoenix.com floridaphoenix.com, CIDRAP cidrap.umn.edu cidrap.umn.edu, and other authoritative sources as cited above. Each development is linked to its original reporting for further reading. The roundup covers events and announcements from August 18–19,
Go toTop